A Disease Seeking Its Identity: Peripheral SpA, PsA, and the SPARTACUS Evidence Save

For years, peripheral spondyloarthritis (pSpA) has been managed with a cautious, stepwise approach: start with NSAIDs, escalate to conventional synthetic DMARDs, and only reach for biologics when everything else fails. The SPARTACUS trial, presented at EULAR 2026 in London (OP0107), challenges that paradigm head-on. The results make a compelling case for rethinking when, not just whether, to deploy TNF inhibitors.

SPARTACUS is a prospective, randomized, double-blind, phase III multicentric trial conducted across Belgium and the Netherlands. It enrolled 97 patients with early active pSpA fulfilling ASAS classification criteria and symptom duration of one year or less, a deliberate extension beyond the narrower 3-month window of the earlier CRESPA trial. Participants were randomized 1:1 to either first-line golimumab (50 mg sc every 4 weeks) or oral methotrexate (15 mg/week, uptitrated to 20 mg at week 4). At week 12, non-responders in both arms had sulfasalazine 2 g/day added on. The primary endpoint was clinical remission — complete absence of arthritis, dactylitis, and enthesitis — at week 24.

The cohort was predominantly male (60%), with a mean age of 39 years and a mean symptom duration of approximately 6 months. Arthritis was present in nearly all patients (97%), enthesitis in 68%, and dactylitis in 34%. Psoriasis was documented in nearly half (49%), and HLA-B27 positivity was observed in 45%. Baseline disease burden was meaningful, with mean CRP of 25 mg/L and ASDAS-CRP of 3.4.

At week 24, 60% of patients in the TNFi induction arm achieved clinical remission, compared to 33% in the csDMARD step-up group — an absolute difference of 28% (95% CI: 8–46%, p=0.003). The odds ratio for remission was 3.1 (95% CI: 1.4–7.3), firmly in favor of early TNFi. Sustained clinical remission at week 24 also favored the TNFi arm: 42% versus 18% (p=0.006).

Secondary outcomes told the same story. At week 24, patients receiving golimumab had significantly lower tender joint counts (1.3 vs. 3.3, p=0.004), swollen joint counts (1.1 vs. 2.5, p=0.006), patient global assessment (2.6 vs. 4.0, p=0.003), and pain scores (2.4 vs. 3.7, p=0.002). The safety profile was reassuring: only one serious adverse event occurred in the TNFi arm (flu-like symptoms requiring hospitalization).

The core message is not just that biologics work better. It is that initiating them early, before irreversible structural and functional consequences accumulate, may represent a genuine therapeutic window for disease interception, not merely symptom control.

The pSpA vs. PsA Debate at EULAR 2026

The SPARTACUS results landed in a congress where a broader, more fundamental question was simmering: is pSpA actually the same disease as PsA, or are they distinct entities that simply share phenotypic overlap?

This debate was formally aired during EULAR 2026. The classification systems themselves reflect the unresolved tension: pSpA is captured under the ASAS framework, while PsA falls under the GRAPPA/CASPAR umbrella. Clinicians routinely encounter patients who fulfill criteria for both, and must decide which disease model, and therefore which treatment algorithm, to apply.

The emerging consensus, supported by growing pathophysiologic and genomic data, is that peripheral SpA and PsA are not interchangeable labels. They differ in immunopathology, in the distribution and character of synovitis, in entheseal involvement patterns, and in their response profiles to specific therapeutic targets. Importantly, the absence of psoriasis in a patient with pSpA is not merely a cosmetic distinction, it may signal a different upstream driver.

The trend at EULAR 2026 was clearly towards recognizing pSpA as a separate diagnostic and therapeutic entity, rather than treating it as an undifferentiated precursor to PsA or a mild variant thereof. This has direct clinical implications: if pSpA is its own disease, it warrants its own evidence base, its own treatment guidelines, and potentially its own target profile. The SPARTACUS trial, conducted entirely within an ASAS-defined pSpA population and not a PsA cohort, is precisely the kind of disease-specific evidence base that this emerging paradigm calls for.

What This Means for Practice

SPARTACUS joins a short but growing list of trials demonstrating that early aggressive intervention in spondyloarthritis outperforms a wait-and-escalate strategy. The question that remains open, and that the ongoing follow-up of SPARTACUS is designed to answer, is whether this early TNFi induction translates into sustained drug-free remission. That would be a paradigm shift of the highest order.

For now, the data support a serious reconsideration of current pSpA treatment recommendations. Waiting for csDMARD failure before offering a TNFi to a patient with early, active p SpA may no longer be the defensible default, particularly if we accept that this is a disease that responds best when intercepted early, in its own right.